Chinese PLA General Hospital (CAR-T cell technology) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
Chinese PLA General Hospital (CAR-T cell technology) General Information
Description
Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.
Contact Information
- 28 fuxing road
- Beijing
- China
Chinese PLA General Hospital (CAR-T cell technology) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.
Request a free trialChinese PLA General Hospital (CAR-T cell technology) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.
Request a free trial